Get started
Author

S.-W Ding

HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses
2018 · Patrizia Amelio, Damien Portevin, et al. · Journal of Virology · 77
PDF
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
2019 · Giuseppe Pantaleo, Holly Janes, et al. · The Lancet HIV · 47
PDF
Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates
2015 · Xiaoying Shen, Ryan Duffy, et al. · Journal of Virology · 43
PDF
Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania
2017 · Patrizia Amelio, Damien Portevin, et al. · PLoS neglected tropical diseases · 39
PDF
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates
2015 · Juan García-Arriaza, Beatriz Perdiguero, et al. · Journal of Virology · 39
DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
2019 · Nadine G. Rouphael, Cecilia Morgan, et al. · Journal of Clinical Investigation · 36
PDF
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein
2020 · Mina C Hosseinipour, Craig Innes, et al. · Clinical Infectious Diseases · 34
PDF
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
2014 · Pierre-Alexandre Bart, Yunda Huang, et al. · Journal of Clinical Investigation · 30
PDF
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost
2018 · Benedikt Asbach, Karen V. Kibler, et al. · Journal of Virology · 27
PDF
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates
2017 · Juan García-Arriaza, Beatriz Perdiguero, et al. · Journal of Virology · 27
PDF
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens
2016 · Benedikt Asbach, Alexander Kliche, et al. · Journal of Virology · 25
Effect of Schistosoma mansoni Infection on Innate and HIV-1-Specific T-Cell Immune Responses in HIV-1-Infected Ugandan Fisher Folk
2016 · Andrew Ekii Obuku, Gershim Asiki, et al. · AIDS Research and Human Retroviruses · 22
PDF
Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses
2021 · Alexandra Hauser, George Carnell, et al. · Vaccines · 16
PDF
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial
2020 · Yves Lévy, Christine Lacabaratz, et al. · PLoS Pathogens · 16
PDF
Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery
2021 · David Peterhoff, Stefanie Thalhauser, et al. · Vaccines · 15
PDF
Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC
2018 · Karen V. Kibler, Benedikt Asbach, et al. · Journal of Virology · 15
PDF
Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses
2019 · Beatriz Perdiguero, Carmen Elena Gómez, et al. · Frontiers in Immunology · 13
PDF
Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector
2019 · M. Giel-Moloney, M. Esteban, et al. · Scientific Reports · 11
PDF
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial
2024 · Nigel Garrett, One Dintwe, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 6
Correction for Kibler et al., “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC”
2019 · Karen V. Kibler, Benedikt Asbach, et al. · Journal of Virology · 4
PDF
Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein
2023 · Beatriz Perdiguero, Alexandra Hauser, et al. · Frontiers in Immunology · 3
PDF
HIV specific Th1 responses are altered in Ugandans with HIV and Schistosoma mansoni coinfection
2023 · Andrew Ekii Obuku, Jacqueline Kyosiimire Lugemwa, et al. · BMC Immunology · 3
PDF
Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study
2022 · Beatriz Perdiguero, Benedikt Asbach, et al. · Frontiers in Immunology · 3
PDF
Effect of high-intensity versus low-intensity praziquantel treatment on HIV disease progression in HIV and Schistosoma mansoni co-infected patients: a randomised controlled trial
2018 · Andrew Abaasa, Gershim Asiki, et al. · Wellcome Open Research · 3
An ENV-GAG MRNA vaccine protects macaques from heterologous TIER-2 SHIV infection
2021 · P. Zhang, Elisabeth Narayanan, et al. · Topics in antiviral medicine · 1
Works count: 29
Citation count: 556
H-index: 15
I10-index: 18
Year
Topic
Type